Overview

* Entrada Therapeutics ( TRDA ) Q3 net loss widens to $44.1 mln from $14.0 mln last year

* Collaboration revenue drops to $1.6 mln from $19.6 mln due to plan completion

* Company extends cash runway into Q3 2027 with $327 mln in cash and securities

Outlook

* Entrada expects to report ELEVATE-44-201 data in Q2 2026

* Company plans to report ELEVATE-45-201 data in mid-2026

* Company's cash runway extended into Q3 2027

Result Drivers

* DMD PROGRAM COSTS - Increased R&D expenses driven by costs related to DMD programs and higher personnel expenses

* COLLABORATION REVENUE DECLINE - Revenue drop attributed to completion of collaboration with Vertex

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $1.61

Collabor mln

ation

Revenue

Q3 EPS -$1.06

Q3 Net -$44.13

Income mln

Q3 -$47.05

Income mln

From

Operatio

ns

Q3 $48.67

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Entrada Therapeutics Inc ( TRDA ) is $18.50, about 62.5% above its November 5 closing price of $6.94

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)